Hepatocellular Carcinoma: Molecular and Genomic Guideline for the Clinician
Overview
Authors
Affiliations
Understanding of the genetic changes and molecular signaling pathways that are active in hepatocellular carcinoma has improved substantially over the last decade. As more information becomes available, it is clear that the prognostication of hepatocellular carcinoma will soon include molecular and genomic "fingerprints" that are unique to each cancer, which will allow more personalized treatment plans for patients as more targeted therapies become available. This article discusses the molecular and genomic changes that are important in hepatocellular carcinoma in order for clinicians to understand the current and forthcoming treatment options for patients with liver cancer.
Expression and prognostic signatures of m6A-related lncRNAs in hepatocellular carcinoma.
Hao K, Li J, Zhang Y, Zhao W, Chen X, Xu J J Cancer Res Clin Oncol. 2022; 149(8):4429-4441.
PMID: 36121511 DOI: 10.1007/s00432-022-04338-x.
Zhang L, Qiao Y, Huang J, Wan D, Zhou L, Lin S Front Med (Lausanne). 2020; 7:556.
PMID: 33072775 PMC: 7534531. DOI: 10.3389/fmed.2020.00556.
Huang K, Dong Z, Cai H, Huang M, Peng Z, Xu L BMC Cancer. 2019; 19(1):364.
PMID: 30999947 PMC: 6472074. DOI: 10.1186/s12885-019-5574-8.
Lin B, Zhou X, Lin S, Wang X, Zhang M, Cao B J Mol Med (Berl). 2017; 95(11):1237-1249.
PMID: 28844099 PMC: 8171496. DOI: 10.1007/s00109-017-1578-5.
Hepatocellular Carcinoma: Current Questions and Future Directions.
Gish R Gastroenterol Hepatol (N Y). 2016; 11(3):182-5.
PMID: 27099588 PMC: 4836587.